- Home
- MGY vs SLNO Comparison
MGY vs SLNO Comparison
Compare MGY & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGY
- SLNO
- Stock Information
- Founded
- MGY 2017
- SLNO 1999
- Country
- MGY United States
- SLNO United States
- Employees
- MGY N/A
- SLNO N/A
- Industry
- MGY Oil & Gas Production
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- MGY Energy
- SLNO Health Care
- Exchange
- MGY Nasdaq
- SLNO Nasdaq
- Market Cap
- MGY 4.2B
- SLNO 3.7B
- IPO Year
- MGY 2017
- SLNO 2014
- Fundamental
- Price
- MGY $22.46
- SLNO $67.16
- Analyst Decision
- MGY Hold
- SLNO Strong Buy
- Analyst Count
- MGY 11
- SLNO 9
- Target Price
- MGY $25.40
- SLNO $116.78
- AVG Volume (30 Days)
- MGY 2.1M
- SLNO 1.3M
- Earning Date
- MGY 10-29-2025
- SLNO 11-04-2025
- Dividend Yield
- MGY 2.67%
- SLNO N/A
- EPS Growth
- MGY N/A
- SLNO N/A
- EPS
- MGY 1.80
- SLNO N/A
- Revenue
- MGY $1,320,826,000.00
- SLNO $32,656,999.00
- Revenue This Year
- MGY $0.69
- SLNO N/A
- Revenue Next Year
- MGY $4.00
- SLNO $181.30
- P/E Ratio
- MGY $12.48
- SLNO N/A
- Revenue Growth
- MGY 0.68
- SLNO N/A
- 52 Week Low
- MGY $19.09
- SLNO $41.50
- 52 Week High
- MGY $29.02
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- MGY 40.87
- SLNO 52.55
- Support Level
- MGY $22.68
- SLNO $66.12
- Resistance Level
- MGY $23.28
- SLNO $72.55
- Average True Range (ATR)
- MGY 0.57
- SLNO 3.44
- MACD
- MGY -0.04
- SLNO 0.46
- Stochastic Oscillator
- MGY 16.77
- SLNO 41.99
About MGY Magnolia Oil & Gas Corporation
Magnolia Oil & Gas Corp is an independent oil and natural gas company engaged in the acquisition, development, exploration, and production of oil, natural gas, and natural gas liquid (NGL) reserves. The company's oil and natural gas properties are located in Karnes County and the Giddings area in South Texas, where the Company targets the Eagle Ford Shale and Austin Chalk formations. Its objective is to generate stock market value over the long term through consistent organic production growth, high full-cycle operating margins, and an efficient capital program with short economic paybacks. The company's operating segment is acquisition, development, exploration, and production of oil and natural gas properties located in the United States.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.